Next Generation Vaccines for Multi-Resistant Bacteria
Discover and develop safe and effective vaccines to overcome infectious challenges threatening global public health
A world free of suffering from infectious diseases
Proxi Biotech's BACTOVAC platform technology offers superior vaccines to overcome the challenge of resistant bacteria
Antimicrobial resistance (AMR) is one of the world's most pressing medical problems. More than 700,000 people die each year from infections resistant to antibiotics. By 2050, such infections are expected to kill 10,000,000 people.
Proxi Biotech, an early stage spin-off from the Serum Institute of Denmark, has developed the BACTOVAC platform technology for detoxification of bacterial toxins. BACTOVAC overcomes main barriers of traditional vaccine developing technologies that allows new, highly needed vaccine to enter market and fight multi-resistant bacteria